Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.300
-0.280 (-7.82%)
At close: Mar 24, 2026, 4:00 PM EDT
3.350
+0.050 (1.52%)
After-hours: Mar 24, 2026, 7:35 PM EDT
Aclaris Therapeutics Employees
As of December 31, 2025, Aclaris Therapeutics had 73 total employees, including 69 full-time and 4 part-time employees. The number of employees increased by 9 or 14.06% compared to the previous year.
Employees
73
Change (1Y)
9
Growth (1Y)
14.06%
Revenue / Employee
$107,205
Profits / Employee
-$889,356
Market Cap
397.96M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 73 | 9 | 14.06% | 69 | 4 |
| Dec 31, 2024 | 64 | -27 | -29.67% | 61 | 3 |
| Dec 31, 2023 | 91 | -14 | -13.33% | 86 | 5 |
| Dec 31, 2022 | 105 | 28 | 36.36% | 100 | 5 |
| Dec 31, 2021 | 77 | 17 | 28.33% | 72 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Maravai LifeSciences Holdings | 435 |
| REGENXBIO | 371 |
| Absci | 157 |
| Entrada Therapeutics | 152 |
| Century Therapeutics | 150 |
| Invivyd | 122 |
| Aura Biosciences | 109 |
| Altimmune | 57 |
ACRS News
- 4 days ago - Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 6 days ago - Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewsWire
- 26 days ago - Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript - Seeking Alpha
- 2 months ago - Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development - GlobeNewsWire